NCT06325683 2026-04-15
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
10 trialsNCT04840589 2026-04-13
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04929041 2026-04-13
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT07011550 2026-03-20
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05928806 2026-02-11
ARCITECT
Hoosier Cancer Research Network
Phase 2 Suspended
NCT05445609 2025-09-19
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Suspended
NCT04268888 2025-02-26
TACE-3
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT04042116 2022-12-20
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
Phase 1/2 Suspended
NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
NCT03704714 2022-08-15
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
Phase 1/2 Suspended